Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918640 · ClinicalTrials.gov registry record · Phase 1
Lurbinectedin in FET-Fused Tumors
A Phase 1 study of Pediatric Cancer and Ewing Sarcoma, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 6
- Study locations
NCT05918640 is a Phase 1 study of Pediatric Cancer and Ewing Sarcoma that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 63 participants, below the 1,489-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT05918640, a Phase 1 study of Pediatric Cancer and Ewing Sarcoma, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
Conditions Studied
Interventions
- DRUG Lurbinectedin
Study Locations (6)
California
- Cedars-Sinai Medical Center - Los Angeles
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2023-07-27 |
| Est. Completion | 2028-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05918640
The ClinicalTrials.gov registry entry for NCT05918640 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,489-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pediatric Cancer appearing as the primary indexed condition, and to 1 intervention - of which Lurbinectedin is the first listed.
NCT05918640 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Iowa, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05918640 about?
NCT05918640 is a clinical study titled "Lurbinectedin in FET-Fused Tumors". The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
What is the current status of trial NCT05918640?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2023-07-27. Estimated completion is 2028-07-30.
What conditions does trial NCT05918640 study?
This clinical trial studies the following conditions: Pediatric Cancer, Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Undifferentiated Sarcoma.
What interventions are being tested in trial NCT05918640?
The interventions under investigation include: Lurbinectedin (DRUG).
Who is sponsoring clinical trial NCT05918640?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05918640 being conducted?
This trial has 6 study locations across California, Iowa, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Durvalumab and Tremelimumab for Pediatric Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Virtual Reality Gaming for Exercise and Mindfulness Among Pediatric Cancer Rehabilitation
COMPLETED · Phase 1
-
LIFE Cancer Survivorship Database for Pediatric Cancer
RECRUITING
-
Multisite Implementation of COMPRENDO
RECRUITING · NA
-
Childhood Cancer Predisposition Study (CCPS)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.